La Rosa Holdings 株価情報 (NASDAQ: LRHC)

最新ニュース La Rosa Holdings (NASDAQ:LRHC) 株価情報

La Rosa Holdings

La Rosa Holdings Corp operates in the U.S. residential real estate market. It is a holding company for agent-centric, technology-integrated, cloud-based, multi-service real estate companies. The company's business is organized based on the services it provides internally to the agents and to the public, which are residential and commercial real estate brokerage, franchising, real estate brokerage education and coaching, and property management. The company has six reportable segments, namely: Real Estate Brokerage Services (Residential), Franchising Services, Coaching Services, Property Management, Real Estate Brokerage Services (Commercial), and Title Settlement and Insurance. It derives maximum revenue from the Real Estate Brokerage Services (Residential) segment.

La Rosa Holdings Corp

Biotech

General

IMMP

Immutep Announces Announces That A 60.8% Response Rate And 90.2% Disease Control Rate, According To RECIST, Has Been Achieved In The Investigator-Initiated INSIGHT-003 Trial As Of The Data-Cut Off Date Of  May 6

~ Horizon Aircraft's unique Cavorite X7 eVTOL becomes the first aircraft in the world to achieve&nbsp;a stable transition using a novel fan-in-wing design ~
TORONTO, May 15, 2025 (GLOBE NEWSWIRE) -- New Horizon Aircraft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOVR#NASDAQ">HOVR</a>), doing business as Horizon Aircraft, an advanced aerospace engineering company and developer of one of the world's first hybrid eVTOL aircraft, announces that it has <a href="https://www.globenewswire.com/Tracker?data=N4q3nLPFvxBw4qGBp0sa9ocHYr-K2qBIhweFaIgKrMR-iz9Y9wpiMSp4lPYTgT0dwIhtZlbhcq-3HGEA-MZG3Ft_nA-w4BM7m2xwTuCP9vhixL5m0KUVQ52jB9UC0uLm">achieved full wing transition</a> of its large-scale prototype aircraft.

News

HOVR

Horizon Aircraft's Cavorite X7 Becomes World's First eVTOL To Achieve Stable Transition With Innovative Fan-In-Wing Design

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Aquestive Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQST#NASDAQ">AQST</a>) with a Buy and maintains $10 price target.

Price Target

Reiteration

Analyst Ratings

AQST

HC Wainwright & Co. Reiterates Buy on Aquestive Therapeutics, Maintains $10 Price Target

On Wednesday, President Donald J. Trump inked a deal with the Qatar government, aiming to create an economic exchange valued at least $1.2 trillion, the White House said in a press release.
Apart from this, President Trump disclosed economic agreements between the United States <a target="_blank" href="https://www.whitehouse.gov/fact-sheets/2025/05/fact-sheet-president-donald-j-trump-secures-historic-1-2-trillion-economic-commitment-in-qatar/" rel="noreferrer noopener">and</a> Qatar totaling over $243.5 billion, which included a significant sale of Boeing Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) aircraft and GE Aerospace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GE#NYSE">GE</a>) engines to Qatar Airways for $96 billion.&nbsp;&nbsp;
In particular, Qatar Airways and Boeing disclosed an agreement for the airline to purchase <a href="https://www.benzinga.com/pressreleases/25/05/n45418445/boeing-and-qatar-airways-announce-historic-order-for-up-to-210-widebody-airplanes" target="_blank" rel="noreferrer noopener">up to 210 widebody aircraft</a>.
This deal sets new records as Boeing&#8217;s largest-ever widebody order and includes the most significant order for 787 Dreamliners and Qatar Airways&#8217; single largest aircraft order to date.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/contracts/25/05/45384460/boeing-welcomes-new-saudi-arabian-partner-avilease-orders-20-fuel-efficient-jets" rel="noreferrer noopener">Boeing Welcomes New Saudi Arabian Partner: AviLease Orders 20 Fuel-Efficient Jets</a>
Additionally, GE Aerospace and Qatar Airways announced a substantial expansion <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/n45422353/ge-aerospace-and-qatar-airways-strengthen-partnership-with-agreement-for-400-ge9x-and-genx-engines" rel="noreferrer noopener">of their long-term collaboration</a>.
Qatar Airways has committed to over 400 engines, including 60 GE9X and 260 GEnx engines, along with additional options and spare units.
This represents the largest widebody engine purchase in GE Aerospace&#8217;s history, intended to power Qatar Airways&#8217; next-generation Boeing 777-9 and Boeing 787 aircraft.
These new agreements reinforce GE Aerospace&#8217;s dedication to Qatar&#8217;s growing aviation sector and build upon a prior order for 188 GE9X engines, bringing the total commitment to 248 of these engines.
Moreover, Parsons Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSN#NYSE">PSN</a>) won 30 significant projects with a total potential value of up to $97 billion.
Major Defense Deals: RTX Corporation&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTX#NYSE">RTX</a>) Raytheon secured a $1 billion U.S.-Qatar deal for counter-drone capabilities, making Qatar the first international buyer of Raytheon&#8217;s FS-LIDS.
Also, General Atomics penned an agreement of around $2 billion for Qatar&#8217;s acquisition of the MQ-9B remotely piloted aircraft system.
Apart from this, the U.S. and Qatar inked a statement of intent to further enhance their security partnership, with potential investments exceeding $38 billion, including support for shared responsibilities at Al Udeid Air Base and future defense capabilities.
All the abovementioned deals are expected to generate billions in investments to bolster American manufacturing, fulfilling the commitment to revitalize domestic production and foster economic growth, the White House said in the press release.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45390422/trump-unveils-historic-and-transformative-600-billion-saudi-deal-predicts-markets-will-go-a-lot-higher" target="_blank" rel="noreferrer noopener">Trump Unveils&#8217; Historic And Transformative&#8217; $600 Billion Saudi Deal, Predicts Markets Will &#8216;Go A Lot Higher&#8217;</a></li>
</ul>
Image by Evan El-Amin via Shutterstock

Equities

Large Cap

Contracts

Trump's $1.2 Trillion 'Made in America' Win: Boeing, GE, And Others Secure Qatar Mega-Deal

Vaxart, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VXRT#NASDAQ">VXRT</a>) today announced that it has received approval from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (HHS), to initiate dosing in the 10,000-participant portion of its ongoing Phase 2b clinical trial evaluating its oral pill COVID-19 vaccine candidate.
The Phase 2b trial is a double-blind, multi-center, randomized, comparator-controlled study. It is designed to evaluate the relative efficacy, safety, and immunogenicity of Vaxart's oral COVID-19 vaccine candidate compared to an approved mRNA COVID-19 vaccine in adults who have previously been vaccinated against COVID-19.
Funding for this award was received under Project NextGen, a $5 billion initiative led by BARDA and the National Institute of Allergy and Infectious Diseases (NIAID) to accelerate and streamline the development of the next generation of innovative COVID-19 vaccines, therapeutics, and enablers. Vaxart's project award through the Rapid Response Partnership Vehicle (RRPV) Consortium is valued at up to $460.7 million. This project has been funded with federal funds from HHS; ASPR; and BARDA, under Other Transaction (OT) number 75A50123D00005.
 &nbsp;

VXRT

Vaxart Receives BARDA Approval To Initiate Dosing In 10,000-participant Portion Of Ongoing Phase 2B Clinical Trial Evaluating Oral Pill COVID-19 Vaccine Candidate

Greenland Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTEC#NASDAQ">GTEC</a>) reported quarterly earnings of $0.29 per share. This is a 61.11 percent increase over earnings of $0.18 per share from the same period last year. The company reported $21.68 million in sales this quarter. This is a 4.60 percent decrease over sales of $22.72 million the same period last year.

Earnings

GTEC

Greenland Technologies Q1 EPS $0.29 Up From $0.18 YoY, Sales $21.68M Down From $22.72M YoY

Adcore (TSX:<a class="ticker" href="https://www.benzinga.com/stock/ADCO#TSX">ADCO</a>) reported quarterly losses of $(0.00) per share. This is a 40 percent increase over losses of $(0.01) per share from the same period last year. The company reported $7.01 million in sales this quarter. This is a 2.11 percent increase over sales of $6.87 million the same period last year.

TSX:ADCO

Adcore Q1 EPS $(0.00) Up From $(0.01) YoY, Sales $7.01M Up From $6.87M YoY

Canaccord Genuity analyst Richard Close maintains HealthStream (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSTM#NASDAQ">HSTM</a>) with a Hold and lowers the price target from $30 to $29.

HSTM

Canaccord Genuity Maintains Hold on HealthStream, Lowers Price Target to $29

AmpliTech Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMPG#NASDAQ">AMPG</a>) FY2025 Revenue expected to be more than $21.00M vs $17.00M Est

Guidance

AMPG

AmpliTech Group Sees FY2025  Revenue expected to be more than $21.00M vs $17.00M Est

Despite growing recognition of long COVID as a serious condition, diagnosed patients have no approved treatment options, with many suffering from debilitating fatigue and brain fog
Evidence suggests sustained inflammation plays a central role in the pathogenesis of long COVID, particularly in the associated cognitive dysfunction and other neurological symptoms1
Bezisterim targets key underlying mechanisms of neuroinflammation, and has demonstrated the potential to reduce chronic symptoms in Alzheimer's disease and Parkinson's disease trials thought to be driven by neuroinflammation
CARSON CITY, Nev., May 15, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIVI#NASDAQ">BIVI</a>), ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced first patient enrollment in the Phase 2 ADDRESS-LC clinical trial (<a href="https://www.globenewswire.com/Tracker?data=R-IqdpCs3gs_rEeE54sUQ09HGlhHVrLDi_eNdk6Sd6Cui8hLTSSErT2USBTISodOAsPR_KhmIBGrgFNjSy8T-PlwGG8YccvhcL8Olet5314_yhHDBSm2hwvhJ08MvnKq-QhoF18jy49Fpyfy7_3-iQ==">NCT06847191</a>) evaluating bezisterim (NE3107) for the treatment of neurological symptoms associated with long COVID. The Company anticipates topline data to be available in the first half of 2026.
Long COVID affects approximately 20 million adults in the US, and millions more worldwide.2,3 Studies estimate that approximately 10-30% of individuals who contract COVID-19 experience lingering symptoms for months or even years, with fatigue, brain fog, and cognitive impairment significantly impacting daily functioning and quality of life.4,5 Despite the growing recognition of long COVID as a serious condition, treatment options remain limited, and many patients struggle to find effective relief for their symptoms.

BIVI

BioVie Enrolls First Patient In Phase 2 ADDRESS-LC Clinical Trial Evaluating Bezisterim For Treatment Of Neurological Symptoms Associated With Long COVID; Expects Topline Data To Be Available In H1 2026

Canaccord Genuity analyst Sumant Kulkarni maintains Annovis Bio (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANVS#NYSE">ANVS</a>) with a Buy and lowers the price target from $26 to $17.

ANVS

Canaccord Genuity Maintains Buy on Annovis Bio, Lowers Price Target to $17

AmpliTech Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMPG#NASDAQ">AMPG</a>) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $(0.08) by 12.5 percent. This is a 81.25 percent increase over losses of $(0.48) per share from the same period last year. The company reported quarterly sales of $3.60 million which beat the analyst consensus estimate of $3.00 million by 19.97 percent. This is a 56.96 percent increase over sales of $2.29 million the same period last year.

Earnings Beats

Earnings Misses

AmpliTech Gr Q1 EPS $(0.09) Misses $(0.08) Estimate, Sales $3.60M Beat $3.00M Estimate

Needham analyst Laura Martin reiterates DoubleVerify Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DV#NYSE">DV</a>) with a Buy and maintains $18 price target.

Needham Reiterates Buy on DoubleVerify Holdings, Maintains $18 Price Target

Canaccord Genuity analyst George Gianarikas maintains Aeva Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEVA#NASDAQ">AEVA</a>) with a Buy and raises the price target from $9.5 to $16.

AEVA

Canaccord Genuity Maintains Buy on Aeva Technologies, Raises Price Target to $16

Incannex Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IXHL#NASDAQ">IXHL</a>) reported quarterly losses of $(0.20) per share. This is a 47.37 percent increase over losses of $(0.38) per share from the same period last year.

IXHL

Incannex Healthcare Q3 EPS $(0.20) Up From $(0.38) YoY

-- Early clinical data indicates that Pre-existing and treatment-induced anti-Ad5 neutralizing antibodies do not impact the safety and effectiveness of PCRX-201 –
-- An oral presentation of the data to be featured at the ASGCT Annual Meeting --
BRISBANE, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced new preliminary data which suggests that clinical immunogenicity does not reduce sustained improvements in knee pain, stiffness and function provided by its gene therapy candidate, PCRX-201 (enekinragene inzadenovec), following local administration in patients with mild, moderate, as well as severe osteoarthritis of the knee. The research findings are being presented during a podium session at the American Society of Gene &amp; Cell Therapy (ASGCT) Annual Meeting in New Orleans on May 15, 2025, at 2:15 CT.

PCRX

Pacira Biosciences: New Preliminary Data Suggests Clinical Immunogenicity Does Not Reduce Sustained Improvements In Knee Pain, Stiffness And Function Provided By Gene Therapy Candidate, PCRX-201

TriSalus Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLSI#NASDAQ">TLSI</a>) confirming FY 2025 guidance of at least 50% revenue growth.

TLSI

TriSalus Life Sciences confirming FY 2025 guidance of at least 50% revenue growth.

Hillenbrand, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HI#NYSE">HI</a>) announced today that Robert "Bob" VanHimbergen, Senior Vice President and Chief Financial Officer, has decided to take another position outside of the company, effective June 27, 2025.
Upon Mr. VanHimbergen's departure, Megan Walke, Vice President, Corporate Controller and Chief Accounting Officer (CAO), will serve as Interim CFO. Ms. Walke has been with Hillenbrand for 14 years, holding key financial leadership roles, including as CAO since May 2022, and formerly worked in public accounting for nine years. The company has engaged a leading executive search firm to conduct a comprehensive search for a permanent CFO.

Management

Hillenbrand Announces Robert "Bob" Vanhimbergen, Senior Vice President And CFO, Has Decided To Take Another Position Outside Of The Company, Effective June 27, 2025; Megan Walke, Vice President, Corporate Controller And Chief Accounting Officer, Will Serve As Interim CFO

AMRX

Amneal Pharmaceuticals Receives FDA Approval For Brekiya Injection In Acute Treatment Of Migraine And Cluster Headaches In Adults

Galectin Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GALT#NASDAQ">GALT</a>) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.20) by 25 percent. This is a 21.05 percent increase over losses of $(0.19) per share from the same period last year.

GALT

Galectin Therapeutics Q1 EPS $(0.15) Beats $(0.20) Estimate

Press Releases

La Rosa Holdings Corp. Strengthens Balance Sheet by Redeeming and Extinguishing a Large Portion of Outstanding Warrants

La Rosa Holdings Corp. Appoints Commercial Real Estate Veteran JM Padron to Lead National Expansion of Commercial Real Estate Division

La Rosa Holdings Corp. Announces $4.96 Million Private Placement to Fund Future Potential Strategic Acquisitions, Reduce Debt, and Strengthen Balance Sheet

La Rosa Holdings Corp. to Expand into Europe with the Engagement of Real Estate Veteran Joaquín Nuevo Alarcón as Area Developer for Spain

La Rosa Holdings Corp. Launches LR Agent Advance, Delivering Commission Advances for its Real Estate Agents

La Rosa Holdings Corp. Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule

La Rosa Holdings Corp. Reports 119% Year-Over-Year Increase in Revenue to $69.4 Million for Fiscal 2024; Surpassed Initial Revenue Guidance by Approximately $4.4 Million

La Rosa Holdings Corp. Strategic Collaboration with Lofty to Drive Agent Productivity and Introduce New Recurring Revenue Stream

La Rosa Holdings Corp. Announces Authorization of Stock Buyback Program

La Rosa Holdings Corp. Reports Strong Q1 2025 Growth at Celebration, FL and BF Prime, Puerto Rico Offices Driven by Increased Agent Count, Revenue, and Transactions

LRHC

Altisource Portfolio Solutions S.A. - Common Stock

Altisource Portfolio

KE Holdings Inc American Depositary Shares (each representing three Class A Ordinary Shares)

Comments

La Rosa Holdings

ニュース

最新ニュース La Rosa Holdings (NASDAQ:LRHC) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル